Has Hector Collazo Santiago received payments from drug or device companies?

Yes. Drug and device makers reported $3,827 in general payments to Hector Collazo Santiago across 110 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hector Collazo Santiago did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hector Collazo Santiago come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hector Collazo Santiago

Pulmonary Disease · San Juan, PRNPI 1912356809

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$3,827in general payments, 2019–2025

Across 110 payments — averaging $34.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$733
Boehringer Ingelheim$708
E.r. Squibb & Sons, L.L.C.$417
Bayer$416
Sanofi$319
Johnson & Johnson$157
plus $1K from 18 others

What the payments were for

Food & beverage$3,75898%
Education$180%
Gifts$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	20	$733
Boehringer Ingelheim	23	$708
E.r. Squibb & Sons, L.L.C.	4	$417
Bayer	6	$416
Sanofi	9	$319
Johnson & Johnson	8	$157
Insmed, Inc.	4	$127
Takeda Pharmaceuticals U.S.A., Inc.	4	$108
Mylan Specialty L.p.	2	$104
AbbVie	4	$98
Chiesi USA, Inc.	3	$86
United Therapeutics Corporation	1	$77
PBG Puerto Rico LLC	3	$74
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$67
Amgen	2	$58
Pfizer	2	$52
Mallinckrodt Hospital Products Inc.	1	$38
Actelion Pharmaceuticals US, Inc.	1	$37
Merck	2	$34
Olympus Latin America, Inc.	1	$32
Bayer Puerto Rico Inc.	3	$28
Mylan LLC	1	$28
Genentech USA, Inc.	1	$19
Sanofi-aventis U.S. LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Adempas$368
NUCALA$125
AREXVY$125
OPDIVO$119
OFEV$119
DUPIXENT$105
ELIQUIS$103

How this compares

$3,827 in reported general payments places this provider in the 65th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate	34	$1,451

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →